181 related articles for article (PubMed ID: 24590476)
1. In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.
De Araújo JS; Da Silva CF; Batista DG; Da Silva PB; Meuser MB; Aiub CA; da Silva MF; Araújo-Lima CF; Banerjee M; Farahat AA; Stephens CE; Kumar A; Boykin DW; Soeiro MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):4191-5. PubMed ID: 24590476
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DG; Meuser MB; Demarque KC; Fulco TO; Araújo JS; Da Silva PB; Da Silva CF; Patrick DA; Bakunova SM; Bakunov SA; Tidwell RR; Oliveira GM; Britto C; Moreira OC; Soeiro MN
Antimicrob Agents Chemother; 2016 Apr; 60(4):2425-34. PubMed ID: 26856830
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.
Timm BL; da Silva PB; Batista MM; da Silva FH; da Silva CF; Tidwell RR; Patrick DA; Jones SK; Bakunov SA; Bakunova SM; Soeiro Mde N
Antimicrob Agents Chemother; 2014 Jul; 58(7):3720-6. PubMed ID: 24752263
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of
da Silva CF; Batista DDGJ; de Araújo JS; Cunha-Junior EF; Stephens CE; Banerjee M; Farahat AA; Akay S; Fisher MK; Boykin DW; Soeiro MNC
Drug Des Devel Ther; 2017; 11():1095-1105. PubMed ID: 28435221
[TBL] [Abstract][Full Text] [Related]
5.
Santos CC; Lionel JR; Peres RB; Batista MM; da Silva PB; de Oliveira GM; da Silva CF; Batista DGJ; Souza SMO; Andrade CH; Neves BJ; Braga RC; Patrick DA; Bakunova SM; Tidwell RR; Soeiro MNC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203486
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo.
Batista Dda G; Batista MM; de Oliveira GM; Britto CC; Rodrigues AC; Stephens CE; Boykin DW; Soeiro Mde N
PLoS One; 2011; 6(7):e22155. PubMed ID: 21814568
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro.
DA Silva CF; Daliry A; DA Silva PB; Akay S; Banerjee M; Farahat AA; Fisher MK; Hu L; Kumar A; Liu Z; Stephens CE; Boykin DW; Correia Soeiro MD
Parasitology; 2011 Dec; 138(14):1863-9. PubMed ID: 21902869
[TBL] [Abstract][Full Text] [Related]
8. Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi.
De Souza EM; da Silva PB; Nefertiti AS; Ismail MA; Arafa RK; Tao B; Nixon-Smith CK; Boykin DW; Soeiro MN
Exp Parasitol; 2011 Feb; 127(2):429-35. PubMed ID: 20971106
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi.
Silva CF; Batista Dda G; Batista MM; Lionel J; Hammer ER; Brun R; Soeiro Mde N
Parasitology; 2014 Mar; 141(3):367-73. PubMed ID: 24553079
[TBL] [Abstract][Full Text] [Related]
10. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
[TBL] [Abstract][Full Text] [Related]
11. Trypanosoma cruzi: desferrioxamine decreases mortality and parasitemia in infected mice through a trypanostatic effect.
Arantes JM; Francisco AF; de Abreu Vieira PM; Silva M; Araújo MS; de Carvalho AT; Pedrosa ML; Carneiro CM; Tafuri WL; Martins-Filho OA; Elói-Santos SM
Exp Parasitol; 2011 Aug; 128(4):401-8. PubMed ID: 21620835
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.
Zhu X; Liu Q; Yang S; Parman T; Green CE; Mirsalis JC; de Nazaré Correia Soeiro M; Mello de Souza E; da Silva CF; da Gama Jaen Batista D; Stephens CE; Banerjee M; Farahat AA; Munde M; Wilson WD; Boykin DW; Wang MZ; Werbovetz KA
Antimicrob Agents Chemother; 2012 Jul; 56(7):3690-9. PubMed ID: 22508306
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against Trypanosoma cruzi.
Dos Santos Petry L; Pillar Mayer JC; de Giacommeti M; Teixeira de Oliveira D; Razia Garzon L; Martiele Engelmann A; Magalhães de Matos AFI; Dellaméa Baldissera M; Dornelles L; Melazzo de Andrade C; Gonzalez Monteiro S
Exp Parasitol; 2021; 226-227():108125. PubMed ID: 34129877
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors.
Silva JJ; Osakabe AL; Pavanelli WR; Silva JS; Franco DW
Br J Pharmacol; 2007 Sep; 152(1):112-21. PubMed ID: 17603548
[TBL] [Abstract][Full Text] [Related]
15. The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice.
Miguel DC; Ferraz ML; Alves Rde O; Yokoyama-Yasunaka JK; Torrecilhas AC; Romanha AJ; Uliana SR
Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):945-8. PubMed ID: 21120371
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
17. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
18. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
[TBL] [Abstract][Full Text] [Related]
19. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
[TBL] [Abstract][Full Text] [Related]
20. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.
Caldas IS; Talvani A; Caldas S; Carneiro CM; de Lana M; da Matta Guedes PM; Bahia MT
Parasitol Res; 2008 Jul; 103(2):413-21. PubMed ID: 18454349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
